CTOs on the Move

ATAI Life Sciences

www.atai.life

 
Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.atai.life
  • 677, Huntington Avenue
    Boston, MA USA 02115
  • Phone: +49.89.2153903

Executives

Name Title Contact Details

Similar Companies

TAU Systems

TAU Systems is a deep-tech company developing the first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company. Led by premier experts in laser-driven particle accelerators, TAU is democratizing access for the progress of biotechnology, nuclear and more.

Innoviva

Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.

ValenzaBio

ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.

Urigen Pharmaceuticals

Urigen Pharmaceuticals is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.